07:00 , Jul 30, 2012 |  BioCentury  |  Emerging Company Profile

BioMotiv: Bridging the gap

BioMotiv LLC began operations in June as the for-profit business end of an initiative by Ohio's University Hospitals that seeks to help physician scientists translate their discoveries and attract industry partners. BioMotiv is aiming to...
07:00 , Mar 15, 2012 |  BC Innovations  |  Strategy

One gap, two approaches

Whereas most academic institutes tackle the translational gap by pushing their assets further along in hopes of attracting an industry partner, Cleveland-based University Hospitals is taking the opposite approach by forming a company that will...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Clinical News

InQu regulatory update

FDA granted 510(k) clearance for InQu for use as a bone graft extender in the spine and as a bone graft substitute in the extremities and pelvis. The product is a biopolymer composite of hyaluronic...
08:00 , Dec 19, 2005 |  BC Week In Review  |  Company News

Galapagos NV, Cresset BioMolecular Discovery Ltd. deal

GLPG's BioFocus division (Saffron Walden, U.K.) will use Cresset's Field Templater in silico molecular field modeling technology to develop compound libraries. BioFocus also has an option to license the technology for medicinal chemistry projects for...
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

Cresset BioMolecular Discovery Ltd. sales and marketing update

Cresset launched its Field Templater in silico technology to identify the 3-dimensional conformation of therapeutics bound to targets. Cresset BioMolecular Discovery Ltd., Hertfordshire, U.K.   Business: Bioinformatics   ...
08:00 , Dec 13, 2004 |  BioCentury  |  Finance

Ebb & Flow

Venture firms are doing two things in this IPO window that they have done less frequently in the past: they are investing in the IPO and they are hanging onto their shares well after the...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

EC Technologies LLC, SomaLogic deal

SomaLogic received an exclusive license to EC Technologies' IP covering SELEX (systemic evolution of ligands through exponential enrichment). The technology is used to identify aptamers, which are short strings of nucleotides that fold into 3-dimensional...
07:00 , Jul 19, 2004 |  BC Week In Review  |  Company News

PamGene International B.V., University of Nottingham deal

PamGene licensed its PamStation 3-dimensional, flow-through microarray platform to the university to automate multiplex amplifiable probe hybridization (MAPH) on the platform. MAPH can determine copy number changes in genomic DNA. The university will initially use...
07:00 , Jul 19, 2004 |  BC Week In Review  |  Company News

Linguagen management update

Linguagen Corp., Cranbury, N.J.   Business: Other   Hired: Scott Horvitz as CFO, formerly CFO, corporate secretary and treasurer of 3-Dimensional Pharmaceuticals Inc.   ...
07:00 , Jul 12, 2004 |  BioCentury  |  Strategy

The venture split

Minding the Seed Gap The venture split The two ends of the venture spectrum are nicely illustrated by the strategies of Atlas Venture and Oxford Bioscience Partners: the former takes very little out of academia, while the...